Abbvie Inc (ABBV)

[Taurus69]

$abbv $88.45 ^ 0.75 (0.86%)
Volume: 7,312,995 @10/12/20 5:52:38 PM EDT

[Taurus69]

$abbv $85.89 ? 0.0 (0.00%)
Volume: 364 @10/07/20 5:13:08 AM EDT

[conix]

ABBV Chart

[Taurus69]

$abbv $90.49 ^ 0.79 (0.88%)
Volume: 5,212,480 @09/14/20 7:49:58 PM EDT

[Taurus69]

$abbv $89.74 ^ 0.09 (0.10%)
Volume: 8,385,750 @09/11/20 7:58:55 PM EDT

[DewDiligence]

ABBV, IMAB ink deal to commercialize IMAB’s anti-CD47 mAb globally (excluding Greater China):

https://finance.yahoo.com/news/abbvie-mab-enter-global-strategic-110000707.html

AbbVie and I-Mab announced today that AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.

… The collaboration established today provides AbbVie with an exclusive global license, excluding greater China, to develop and commercialize lemzoparlimab. Both companies will collaborate to design and conduct further global clinical trials to evaluate lemzoparlimab in multiple cancers. I-Mab retains all rights to develop and to commercialize lemzoparlimab in mainland China, Macau and Hong Kong. The collaboration also allows for potential collaboration on future CD47-related therapeutic agents. Each party will have the opportunity subject to further licenses to explore each other's related programs in their respective territories.

The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply. The collaboration will accelerate I-Mab's establishment of commercial production operations in China.

…Under the terms of the agreement, AbbVie will pay I-Mab USD 180 million in an upfront payment to exclusively license lemzoparlimab, along with USD 20 million in a milestone payment based on the phase 1 results, for a total of USD 200 million.

In addition, I-Mab will be eligible to receive up to USD 1.74 billion in success-based milestone payments for lemzoparlimab, of which USD 840 million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China.

[conix]

ABBV Chart

[Taurus69]

$abbv $94.86 v -0.34 (-0.36%)
Volume: 5,276,641 @08/21/20 7

[Argaponis]

Good for ABBVIE delay for Gilead Sciences & (galapagos) rheumatoid arthritis (RA)


Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA). The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. Gilead is the market authorization holder for filgotinib in the United States and is responsible for potential commercialization in the U.S.

The FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose.

“We are disappointed in this outcome and will evaluate the points raised in the CRL for discussion with the FDA. We continue to believe in the benefit/risk profile of filgotinib in RA, which has been demonstrated in the FINCH Phase 3 clinical program,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

“This CRL issued by the FDA is very disappointing given the robust and comprehensive data package provided. Despite today’s news, we continue to believe filgotinib has the potential to provide an effective, new treatment option for patients with rheumatoid arthritis, where there remains a significant unmet need,” said Dr. Walid Abi-Saab, Chief Medical Officer, Galapagos.

The MANTA and MANTA-RAy studies are fully recruited, with topline results anticipated in the first half of 2021. Filgotinib is currently under review by regulatory authorities around the world. Filgotinib recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending marketing authorization for filgotinib in the EU for the treatment of adults with moderate to severe RA who have responded inadequately or are intolerant of one or more disease-modifying anti-rheumatic drugs.

[Taurus69]

$abbv $92.8 ^ 0.23 (0.25%)
Volume: 5,227,110 @08/07/20 7:59:47 PM EDT

[Taurus69]

$abbv $94.31 v -1.63 (-1.70%)
Volume: 7,865,116 @08/04/20 7:58:12 PM EDT

[DewDiligence]

ABBV 2Q20 CC transcript:

https://finance.yahoo.com/m/72e19094-2a74-319d-aa5f-082cb3eec319/abbvie-(abbv)-q2-2020.html

[DewDiligence]

ABBV 2Q20 results/full-year-2020 guidance:

https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2020-financial-results.htm

New 2020 non-GAAP EPS guidance = $10.35-10.45, including $0.70 accretion from AGN acquisition.

[DewDiligence]

Atogepant phase-3 succeeds in migraine prevention:

https://finance.yahoo.com/news/abbvie-announces-positive-phase-3-124500900.html

[Taurus69]

$abbv $100.83 ^ 0.91 (0.91%)
Volume: 6,896,147 @07/17/20 7:51:43 PM EDT

[Taurus69]

$abbv $99.01

[DewDiligence]

ABBV’s DARPin receives CRL in AMD due to still-high rate of intraocular inflammation:

https://www.prnewswire.com/news-releases/allergan-an-abbvie-company-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol-301084188.html

Allergan, an AbbVie Company, and Molecular Partners (MOLN.SW)…today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License Application (BLA) for Abicipar pegol, a novel, investigational DARPin therapy for patients with neovascular (wet) age-related macular degeneration (nAMD).

The letter from the FDA indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results in an unfavorable benefit-risk ratio in the treatment of neovascular (wet) age-related macular degeneration (AMD).

Inasmuch as Abicipar pegol was reformulated to reduce intraocular inflammation from 15% to 9% (#msg-147952065), this CRL probably spells the end of the program.

[DewDiligence]

FDA approves Voluma for chin enhancement:

https://finance.yahoo.com/news/fda-approves-juv-derm-voluma-121500053.html

[TFMG]

$ABBV On breakout watch above $100



P/E ratio 17.15
Company profile
AbbVie , Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

[Taurus69]

$abbv $92.46 ^ 0.2 (0.22%)

[osama]

This is the biggest theft in history for human pockets. Why do companies not rise dramatically when the market jumps 1700 points! But when the market goes down, all companies scramble with the Dow

[$Pistol Pete$]

Nice close

[Taurus69]

$abbv $93.85 ^ 0.81 (0.87%)

[DewDiligence]

ABBV forms collaboration to develop COVID-19 antibody for prophylaxis and treatment:

https://www.prnewswire.com/news-releases/abbvie-harbour-biomed-utrecht-university-and-erasmus-medical-center-announce-collaboration-to-develop-monoclonal-antibody-therapy-to-prevent-and-treat-covid-19-301071164.html

[Taurus69]

$abbv $92.67 ^ 2.64 (2.93%)

[Taurus69]

$abbv $93.02

[conix]

ABBV Chart

[osama]

can any one explain why ABBV not moving it should be over 100$

[DewDiligence]

ABBV completes $65B AGN acquisition:

https://www.allergan.com/News/Details/2020/05/AbbVie%20Inc%20Completes%20Acquisition%20of%20Allergan%20plc

The deal, announced in Jun 2019 (#msg-149577810), entitles each AGN share to receive 0.886 shares of ABBV plus $120.30 in cash, a nominal value of $194.69/sh (3% higher than the nominal value of $188.24/sh nominal value at the time of the deal announcement).

[DewDiligence]

1Q20 worldwide Botox sales=$812.2M, -6% YoY, -20% QoQ*:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155520490

[Taurus69]

$abbv $84.22

[DewDiligence]

ABBV-AGN merger expected to close 5/8/20:

https://finance.yahoo.com/news/announcement-relating-outcome-court-sanction-105500126.html

[DewDiligence]

The AGN deal closing won't materailly affect ABBV's share price one way or the other.

[osama]

please can any one advice what will happen to ABBV stock the time they finalize acquisition of Allergan is the stock goes up or done i mean when ABBV bay 63 bln$

[Taurus69]

$abbv $82.84

[DewDiligence]

ABBV 1Q20 CC transcript:

https://finance.yahoo.com/news/edited-transcript-abbv-earnings-conference-233146513.html

[DewDiligence]

ABBV 1Q20 results—no change in 2020 non-GAP EPS guidance:

https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-first-quarter-2020-financial-results

AGN acquisition still slated for closing in May 2020.

[Taurus69]

$abbv $82.2

[Taurus69]

$abbv $83.59

[Taurus69]

$abbv $82.04

[Taurus69]

$abbv $83.99

[Easka]

I say $82.31!

[Taurus69]

$abbv $81.82

[Taurus69]

$abbv $79.75

[Taurus69]

$abbv $73.37

[Taurus69]

$abbv $73.42

[conix]

ABBV 5 Year Chart

candles=redgreenp[/chart]

[Solar_Express]

Nice buy for longer term. Nice pipeline. Found this doing some DD on REIT NRZ.

[Taurus69]

$abbv ABBVIE (NYSE:ABBV) DIVIDEND INFORMATION

AbbVie pays an annual dividend of $4.72 per share, with a dividend yield of 6.86%. ABBV's next quarterly dividend payment will be made to shareholders of record on Friday, May 15. The company has grown its dividend for the last 47 consecutive years and is increasing its dividend by an average of 22.62% each year. AbbVie pays out 52.80% of its earnings out as a dividend.
Next Dividend: 5/15/2020
Annual Dividend: $4.72
Dividend Yield: 6.86%
Dividend Growth: 22.62% (3 Year Average)
Payout Ratio(s): 52.80% (Trailing 12 Months of Earnings)
44.87% (Based on This Year's Estimates)
39.93% (Based on Next Year's Estimates)
47.19% (Based on Cash Flow)
Track Record: 47 Years of Consecutive Dividend Growth
Frequency: Quarterly Dividend
Most-Recent Increase: $0.11 increase on 11/1/2019

[Taurus69]

$abbv Share Structure

Market Cap Market Cap
101,795,562,924
03/20/2020
Authorized Shares
Not Available
Outstanding Shares
1,479,156,683
01/31/2020
Restricted